MacroGenics Schedules March Investor Roadshow Across Four Major Healthcare Conferences

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

MacroGenics to participate in four major healthcare investor conferences in March 2026, with management presenting on pipeline developments and business operations.

MacroGenics Schedules March Investor Roadshow Across Four Major Healthcare Conferences

MacroGenics, Inc. announced its participation in four prominent investor conferences scheduled for March 2026, positioning the company for increased engagement with institutional investors and market participants. The biopharmaceutical company's management team, led by President and Chief Executive Officer Eric Risser, will attend the TD Cowen, Leerink Partners, Citizens, and Barclays healthcare conferences, providing investors with direct access to company leadership.

The company plans to conduct formal presentations alongside fireside chat sessions and facilitate one-on-one meetings with investors at each event. This multi-conference roadshow represents a standard corporate communications strategy employed by biopharmaceutical firms to maintain investor relations and provide market updates on pipeline developments and business operations.

Webcast recordings of the company's presentations will be made available through MacroGenics' investor relations website, extending access to presentations beyond conference attendees. This approach allows broader market participation and provides investors with on-demand access to management commentary regarding the company's strategic priorities and financial performance outlook.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 26

Related Coverage

GlobeNewswire Inc.

Biofrontera to Report Q1 2026 Results as PDT Expansion Accelerates

Biofrontera to report Q1 2026 results May 14, advancing Ameluz® commercialization and clinical expansion into skin cancers and acne.

BFRIBFRIW
GlobeNewswire Inc.

Arcutis Bolsters Team With $269K RSU Grants as FDA Expands ZORYVE Potential

Arcutis granted 309,000 equity awards to 40 new hires. Company seeks FDA approval to expand ZORYVE cream to treat atopic dermatitis in infants as young as 3 months.

ARQT
GlobeNewswire Inc.

Pharvaris Raises $115M to Advance Rare Disease Pipeline

Pharvaris raises $115M through 3.87M share offering at $29.68 per share to advance oral angioedema treatments; Phase 3 data expected Q3 2026.

PHVS
GlobeNewswire Inc.

PARP Inhibitor Pipeline Surges: 25+ Pharma Giants Race to Expand Cancer Drug Arsenal

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.

AZNGILDALLR
Benzinga

Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1B in Rare Disease Push

Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion at $31.50 per share, with concurrent patent litigation resolution for rare disease drug Firdapse.

CPRX
GlobeNewswire Inc.

Novartis Expands Radioligand Therapy Network with Texas Facility Groundbreaking

Novartis broke ground on a $46K sq. ft. radioligand therapy facility in Texas, the fifth RLT site supporting its $23B US manufacturing investment ending in 2028.

NVS